|
1
|
Olson E, Wintheiser G, Wolfe KM, Droessler
J and Silberstein PT: Epidemiology of thyroid cancer: A review of
the national cancer database, 2000-2013. Cureus.
11(e4127)2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kim J, Gosnell JE and Roman SA: Geographic
influences in the global rise of thyroid cancer. Nat Rev
Endocrinol. 16:17–29. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Nettore IC, Colao A and Macchia PE:
Nutritional and environmental factors in thyroid carcinogenesis.
Int J Environ Res Public Health. 15(1735)2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Cabanillas ME, McFadden DG and Durante C:
Thyroid cancer. Lancet. 388:2783–2795. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Hahn LD, Kunder CA, Chen MM, Orloff LA and
Desser TS: Indolent thyroid cancer: Knowns and unknowns. Cancers
Head Neck. 2(1)2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kreissl MC, Janssen MJR and Nagarajah J:
Current treatment strategies in metastasized differentiated thyroid
cancer. J Nucl Med. 60:9–15. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Khatami F, Larijani B, Nikfar S, Hasanzad
M, Fendereski K and Tavangar SM: Personalized treatment options for
thyroid cancer: Current perspectives. Pharmgenomics Pers Med.
12:235–245. 2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Nixon AM, Provatopoulou X, Kalogera E,
Zografos GN and Gounaris A: Circulating thyroid cancer biomarkers:
Current limitations and future prospects. Clin Endocrinol (Oxf).
87:117–126. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Li Q, Li H, Zhang L, Zhang C, Yan W and
Wang C: Identification of novel long non-coding RNA biomarkers for
prognosis prediction of papillary thyroid cancer. Oncotarget.
8:46136–46144. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Chou CK, Liu RT and Kang HY:
MicroRNA-146b: A novel biomarker and therapeutic target for human
papillary thyroid cancer. Int J Mol Sci. 18(636)2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Lam EW, Brosens JJ, Gomes AR and Koo CY:
Forkhead box proteins: Tuning forks for transcriptional harmony.
Nat Rev Cancer. 13:482–495. 2013.PubMed/NCBI View
Article : Google Scholar
|
|
12
|
Chiu YC, Li MY, Liu YH, Ding JY, Yu JY and
Wang TW: Foxp2 regulates neuronal differentiation and neuronal
subtype specification. Dev Neurobiol. 74:723–738. 2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Tsui D, Vessey JP, Tomita H, Kaplan DR and
Miller FD: FoxP2 regulates neurogenesis during embryonic cortical
development. J Neurosci. 33:244–258. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Co M, Anderson AG and Konopka G: FOXP
transcription factors in vertebrate brain development, function and
disorders. Wiley Interdiscip Rev Dev Biol. 9(e375)2020.PubMed/NCBI View
Article : Google Scholar
|
|
15
|
Jia WZ, Yu T, An Q, Yang H, Zhang Z, Liu X
and Xiao G: MicroRNA-190 regulates FOXP2 genes in human gastric
cancer. Onco Targets Ther. 9:3643–3651. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ren T, Liu C, Hou J and Shan F:
Hsa_circ_0043265 suppresses proliferation, metastasis, EMT and
promotes apoptosis in non-small cell lung cancer through
miR-25-3p/FOXP2 pathway. Onco Targets Ther. 13:3867–3880.
2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Sun T, Guan Q, Wang Y, Qian K, Sun W, Ji
Q, Wu Y, Guo K and Xiang J: Identification of differentially
expressed genes and signaling pathways in papillary thyroid cancer:
A study based on integrated microarray and bioinformatics analysis.
Gland Surg. 10:629–644. 2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ni Z, Lu W, Li Q, Han C, Yuan T, Sun N and
Shi Y: Analysis of the HNF4A isoform-regulated transcriptome
identifies CCL15 as a downstream target in gastric carcinogenesis.
Cancer Biol Med. 18:530–546. 2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Manfredi GI, Dicitore A, Gaudenzi G,
Caraglia M, Persani L and Vitale G: PI3K/Akt/mTOR signaling in
medullary thyroid cancer: A promising molecular target for cancer
therapy. Endocrine. 48:363–370. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Petrulea MS, Plantinga TS, Smit JW,
Georgescu CE and Netea-Maier RT: PI3K/Akt/mTOR: A promising
therapeutic target for non-medullary thyroid carcinoma. Cancer
Treat Rev. 41:707–713. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Mei Y, Liao X, Zhu L and Yang H:
Overexpression of RSK4 reverses doxorubicin resistance in human
breast cancer cells via PI3K/AKT signalling pathway. J Biochem.
167:603–611. 2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Serra V, Eichhorn PJ, García-García C,
Ibrahim YH, Prudkin L, Sánchez G, Rodríguez O, Antón P, Parra JL,
Marlow S, et al: RSK3/4 mediate resistance to PI3K pathway
inhibitors in breast cancer. J Clin Invest. 123:2551–2563.
2013.PubMed/NCBI View
Article : Google Scholar
|
|
24
|
Katoh M and Katoh M: Human FOX gene family
(review). Int J Oncol. 25:1495–1500. 2004.PubMed/NCBI
|
|
25
|
Herrero MJ and Gitton Y: The untold
stories of the speech gene, the FOXP2 cancer gene. Genes Cancer.
9:11–38. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Lang X, Zhang W, Song X, Zhang G, Du X,
Zhou Y, Li Z and Zhang XY: FOXP2 contributes to the cognitive
impairment in chronic patients with schizophrenia. Aging (Albany
NY). 11:6440–6448. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wu J, Liu P, Tang H, Shuang Z, Qiu Q,
Zhang L, Song C, Liu L, Xie X and Xiao X: FOXP2 promotes tumor
proliferation and metastasis by targeting GRP78 in triple-negative
breast cancer. Curr Cancer Drug Targets. 18:382–389.
2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Plata-Bello J, Fariña-Jerónimo H, Betancor
I and Salido E: High expression of FOXP2 is associated with worse
prognosis in glioblastoma. World Neurosurg. 150:e253–e278.
2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Nishida K, Kuwano Y and Rokutan K: The
MicroRNA-23b/27b/24 cluster facilitates colon cancer cell migration
by targeting FOXP2. Cancers (Basel). 12(174)2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Diao H, Ye Z and Qin R: miR-23a acts as an
oncogene in pancreatic carcinoma by targeting FOXP2. J Investig
Med. 66:676–683. 2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Chen MT, Sun HF, Li LD, Zhao Y, Yang LP,
Gao SP and Jin W: Downregulation of FOXP2 promotes breast cancer
migration and invasion through TGFβ/SMAD signaling pathway. Oncol
Lett. 15:8582–8588. 2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Yan X, Zhou H and Zhang T, Xu P, Zhang S,
Huang W, Yang L, Gu X, Ni R and Zhang T: Downregulation of FOXP2
promoter human hepatocellular carcinoma cell invasion. Tumour Biol.
36:9611–9619. 2015.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Cuiffo BG, Campagne A, Bell GW, Lembo A,
Orso F, Lien EC, Bhasin MK, Raimo M, Hanson SE, Marusyk A, et al:
MSC-regulated microRNAs converge on the transcription factor FOXP2
and promote breast cancer metastasis. Cell Stem Cell. 15:762–774.
2014.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Wong KK, Gascoyne DM, Soilleux EJ, Lyne L,
Spearman H, Roncador G, Pedersen LM, Møller MB, Green TM and Banham
AH: FOXP2-positive diffuse large B-cell lymphomas exhibit a poor
response to R-CHOP therapy and distinct biological signatures.
Oncotarget. 7:52940–52956. 2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Khan FH, Pandian V, Ramraj S, Natarajan M,
Aravindan S, Herman TS and Aravindan N: Acquired genetic
alterations in tumor cells dictate the development of high-risk
neuroblastoma and clinical outcomes. BMC Cancer.
15(514)2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Gascoyne DM, Spearman H, Lyne L, Puliyadi
R, Perez-Alcantara M, Coulton L, Fisher SE, Croucher PI and Banham
AH: The forkhead transcription factor FOXP2 is required for
regulation of p21WAF1/CIP1 in 143B osteosarcoma cell growth arrest.
PLoS One. 10(e0128513)2015.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Garcia-Alonso L, Iorio F, Matchan A,
Fonseca N, Jaaks P, Peat G, Pignatelli M, Falcone F, Benes CH,
Dunham I, et al: Transcription factor activities enhance markers of
drug sensitivity in cancer. Cancer Res. 78:769–780. 2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Bushweller JH: Targeting transcription
factors in cancer-from undruggable to reality. Nat Rev Cancer.
19:611–624. 2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Thakur A, Rahman KW, Wu J, Bollig A,
Biliran H, Lin X, Nassar H, Grignon DJ, Sarkar FH, Liao JD, et al:
Aberrant expression of X-linked genes RbAp46, Rsk4 and Cldn2 in
breast cancer. Mol Cancer Res. 5:171–181. 2007.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Houles T and Roux PP: Defining the role of
the RSK isoforms in cancer. Semin Cancer Biol. 48:53–61.
2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Li Q, Jiang Y, Wei W, Ji Y, Gao H and Liu
J: Frequent epigenetic inactivation of RSK4 by promoter methylation
in cancerous and non-cancerous tissues of breast cancer. Med Oncol.
31(793)2014.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Niskakoski A, Kaur S, Staff S,
Renkonen-Sinisalo L, Lassus H, Järvinen HJ, Mecklin JP, Bützow R
and Peltomäki P: Epigenetic analysis of sporadic and
Lynch-associated ovarian cancers reveals histology-specific
patterns of DNA methylation. Epigenetics. 9:1577–1587.
2014.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Hu C, Dai J, Lin X, Meng Y and Liang H:
Effect of RSK4 on biological characteristics of gastric cancer.
Cancer Manag Res. 12:611–619. 2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Guerrero-Zotano A, Mayer IA and Arteaga
CL: PI3K/AKT/mTOR: Role in breast cancer progression, drug
resistance and treatment. Cancer Metastasis Rev. 35:515–524.
2016.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Wang N, Li Y, Wei J, Pu J, Liu R, Yang Q,
Guan H, Shi B, Hou P and Ji M: TBX1 functions as a tumor suppressor
in thyroid cancer through inhibiting the activities of the PI3K/AKT
and MAPK/ERK pathways. Thyroid. 29:378–394. 2019.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Myers AP, Corson LB, Rossant J and Baker
JC: Characterization of mouse Rsk4 as an inhibitor of fibroblast
growth factor-RAS-extracellular signal-regulated kinase signaling.
Mol Cell Biol. 24:4255–4266. 2004.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Grunt TW and Mariani GL: Novel approaches
for molecular targeted therapy of breast cancer: Interfering with
PI3K/AKT/mTOR signaling. Curr Cancer Drug Targets. 13:188–204.
2013.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Arcaro A and Guerreiro AS: The
phosphoinositide 3-kinase pathway in human cancer: Genetic
alterations and therapeutic implications. Curr Genomics. 8:271–306.
2007.PubMed/NCBI View Article : Google Scholar
|
